New Two-Pronged attack tested for Tough-to-Treat prostate cancer
NCT ID NCT07244393
Summary
This early-stage trial is testing the safety of a new two-drug combination for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. The treatment pairs a radioactive drug that targets cancer cells with an immunotherapy drug designed to help the immune system fight the cancer. The study will enroll about 30 participants to see if the combination is safe and if it shows early signs of slowing the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.